A prospective observational study of osimertinib as predictive marker against patients with EGFR T790M-positive NSCLC.
Not Applicable
- Conditions
- ung Cancer
- Registration Number
- JPRN-UMIN000027233
- Lead Sponsor
- Gunma University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
1)Active double cancer 2)Interstitial pneumonitis on chest CT 3)Symptomatic brain metastases 4)Uncontrollable pleural effusion or pericardial effusion 5)Active infectious disease 6)No allogeneic bone marrow transplant
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoint:To predict the efficacy of osimertinib according to quantitative amount of T790M expression. Secandary endpoint:To predict the efficacy of osimertinib according to quantitative amount of C797S.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie osimertinib's efficacy in EGFR T790M-positive NSCLC patients?
How does osimertinib compare to other EGFR inhibitors in treating T790M-positive NSCLC?
Which biomarkers correlate with osimertinib response in EGFR T790M-positive lung cancer?
What are the common adverse events associated with osimertinib in NSCLC treatment?
Are there combination therapies with osimertinib showing improved outcomes for EGFR T790M-positive NSCLC?